The CVHB937A12201 Study is looking to find out more about an investigational medication (called a study drug) in people with mild AD. We want to look at the study drug to see if it has an effect on a person’s ability to think and remember, and causes serious side effects. To do this, the study ... Read More
The DFP study aims to create a database of different measures taken by people at risk of Alzheimer’s disease. The measures include regular brain scans, cognitive and memory tests, scans of magnetic fields generated by the brain, retinal imaging, blood tests, and the use of wearable technology to ... Read More
The ISAP Study led in collaboration between the Diabetes Trial Unit and the Department of Psychiatry at the University of Oxford and Novo Nordisk will examine whether semaglutide, a tablet used to treat diabetes, can change the course of the earliest changes that happen in the brains of people at ... Read More
Alzheimer’s disease begins long before symptoms show. The ReTain study is evaluating whether an investigational medication is safe, tolerable and effective at slowing the onset of Alzheimer’s disease symptoms for those who may be at risk. ... Read More
The WN45447 study aims to determine if an experimental drug can help slow down Alzheimer’s disease. WN45447 will include approximately 800 adults who have a recent diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease. Mild cognitive impairment means having problems with ... Read More
